Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03986034 ·Status: RECRUITING ·Phase: PHASE2

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756 ·Status: RECRUITING ·Phase: PHASE2

Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens

NCT04790045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

NCT04178317 ·Status: COMPLETED

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436 ·Status: RECRUITING ·Phase: PHASE2

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

NCT04198415 ·Status: COMPLETED

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

NCT03513562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

NCT04285567 ·Status: COMPLETED ·Phase: PHASE3

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia

NCT03455517 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05105841 ·Status: COMPLETED ·Phase: PHASE2

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

NCT03739554 ·Status: COMPLETED ·Phase: PHASE1

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

NCT06958705 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

NCT05918198 ·Status: RECRUITING ·Phase: PHASE2

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

NCT05182385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Venetoclax Registry

NCT03662724 ·Status: RECRUITING

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

NCT03319901 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Venetoclax Based Regimen for R/R T-ALL

NCT05149378 ·Status: COMPLETED ·Phase: PHASE2

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

NCT01685892 ·Status: COMPLETED ·Phase: PHASE1

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

NCT02670044 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424 ·Status: RECRUITING ·Phase: PHASE1

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019 ·Status: RECRUITING ·Phase: PHASE3

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

NCT04616274 ·Status: RECRUITING

Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

NCT07039877 ·Status: RECRUITING ·Phase: PHASE2